Table 7. Health outcomes per cohort for the overall AMPLE population after 2 years (ABA-1L vs. ABA-2L+).
| ABA-1L | ABA-2L+ | Incremental number of patients achieving endpoint (ABA-1L –ABA-2L+) | |
|---|---|---|---|
| Total number of responding patients | |||
| ACR50 | 112.68 | 98.59 | 14.08 |
| J-HAQ | 183.10 | 112.68 | 70.42 |
| Total number of patients in remission | |||
| CDAI | 267.61 | 154.93 | 112.68 |
| SDAI | 267.61 | 154.93 | 112.68 |
| Total number of patients discontinuing treatment | |||
| Any reason | 267.61 | 436.62 | -169.01 |
| Total number of patients with an adverse event | |||
| Serious adverse events | 234.41 | 250.28 | -15.87 |
1L, first line; 2L+, second or later line; ABA, abatacept; ACR50, American College of Rheumatology response of at least 50% improvement; CDAI, Clinical Disease Activity Index; J-HAQ, Japanese version of Health Assessment Questionnaire; SDAI, Simplified Disease Activity Index.